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controversial in patients with CKD not on renal replacement. Recently, Go and colleagues utilized a large administrative database containing data from 10 908 AF patients to demonstrate that a lower level of eGFR was associated with a graded, increased risk of ischaemic stroke and other systemic embolism which was independent of known risk factors in AF. 5 In patients with an eGFR of ,45 mL/min, stroke risk was 4.22 per 100 patient-years. Mechanisms underlying the increased stroke risk in CKD are likely to be multifactorial but include augmentation of the underlying prothrombotic diathesis by several pathways. Despite this increased risk for AF-associated thromboembolism, many patients with CKD are not receiving oral anticoagulation therapy, 6 mostly because of fear of bleeding with warfarin. In fact, it has been shown that the risk of bleeding associated with warfarin therapy is particularly high in patients with CKD. 7 Hence, there is a formidable clinical dilemma in AF patients who are concomitantly suffering from renal disease. Recently, several new oral anticoagulants have been tested in large trials involving thousands of patients with AF. 8 -10 All of these new anticoagulants are partially eliminated by renal clearance. In CKD patients, therefore, the half-lives of these novel anticoagulants may be prolonged, resulting in enhanced antithrombotic efficacy. On the other hand, there might be a higher than normal bleeding risk in CKD patients with these compounds.
The ROCKET-AF study tested the efficacy and safety of rivaroxaban, a novel factor Xa inhibitor, in 14 264 patients with non-valvular AF and additional stroke risk factors compared with standard warfarin therapy aiming at an international normalized ratio (INR) of 2.0 -3.0. 10 Rivaroxaban is predominantly metabolized by the liver, but approximately one-third of the drug is cleared by the kidneys. 11, 12 The ROCKET-AF trial excluded patients with an eGFR ,30 mL/min, whereas the daily dose of rivaroxaban was reduced from 20 to 15 mg in patients with an eGFR of 30 -49 mL/min based on available pharmacodynamic data and pharmacokinetic modelling. 13 Fox and colleagues have now reported the results from a substudy of ROCKET-AF in 2950 subjects with moderate renal impairment. 14 In agreement with previous studies, patients with moderate kidney dysfunction had at baseline more concomitant disease burden including higher prevalence of prior myocardial infarction, heart failure, and peripheral vascular disease. Compared with subjects with normal renal function, patients with CKD had a higher incidence of stroke and systemic embolic events, irrespective of the treatment assignment (i.e. warfarin or rivaroxaban). This observation confirms results of studies evaluating the direct thrombin inhibitor dabigatran 8 or the novel factor Xa inhibitor apixaban 9 where strokes and systemic embolic events were
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more frequent among patients with impaired renal function. In ROCKET-AF, the efficacy results in patients with reduced eGFR were consistent with the results observed in the overall study population (see Table 1 ) with a non-significant interaction P-value of 0.76. Specifically, the HR for the primary outcome measure of stroke/systemic embolic events was 0.84 in patients with reduced and 0.78 in patients with normal eGFR. Importantly, the benefit of rivaroxaban in terms of stroke prevention did not come at the expense of a higher bleeding rate. Major and clinically relevant bleeds (primary safety outcome in ROCKET-AF) were more frequently observed in CKD patients irrespective of treatment assignment. However, there was no excess bleeding on rivaroxaban compared with warfarin. Of note, critical organ bleeding and fatal bleeds were actually less frequently encountered with rivaroxaban than with warfarin.
In summary, therefore, we now have important data from three novel anticoagulants regarding stroke prevention in AF patients with CKD. The benefits of these new anticoagulants in patients with CKD were consistent with those in the overall study populations. Of note, rivaroxaban, 14 dabigatran, 15 and apixaban 9 were not associated with higher bleeding rates in CKD. In all three studies, however, patients with an eGFR ,30 mL/min were excluded. Accordingly, there is still a paucity of data in AF patients with more severe degrees of CKD and in those on renal replacement therapy. 
